Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-Phenylcaine Forte versus Co-Phenylcaine Neo for nasendoscopy
ACTRN12619001493134Phase 3Not yet recruiting
- Sponsor
- Curtin University
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lidocaine + phenylephrine and Co-Phenylcaine Neo (2 arms), sponsored by Curtin University. Primary endpoint: Discomfort after nasendoscopy. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
lidocaine + phenylephrineCo-Phenylcaine Neo
Beyond the preview
Go deeper on ACTRN12619001493134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001493134.